Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- Registration Number
- NCT00255281
- Lead Sponsor
- AstraZeneca
- Brief Summary
The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
- Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity
Exclusion Criteria
- Clinically significant sinus and/or AV node dysfunction. Serum or plasma potassium <3.8 mmol/L or >5.0 mmol/L. QTc(Bazett) >450 ms. Any QRS duration >150 ms
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The proportion of patients that have converted from AF within 90 minutes from start of infusion.
- Secondary Outcome Measures
Name Time Method The time to conversion of AF from start of the infusion.
Trial Locations
- Locations (1)
Research Site
πΈπͺStockholm, Sweden